Trial Profile
Idiopathic Pulmonary Fibrosis International Group Exploring NAC I Annual Study of the Effects of High-Dose N-Acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Acetylcysteine (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Registrational; Therapeutic Use
- Acronyms IFIGENIA
- Sponsors Zambon SpA
- 04 Apr 2014 New trial record